Evidence map›Paper›PMID 42069682›Full record

ArticleCell death & disease2026

BAP1 and USP1 cooperate to regulate FANCD2 stability and cell proliferation in mesothelioma cells.

Koya Suzuki, Shinichi Kiyonari, Jo Nishino, Miki Takahashi, Yuna Kato, Miki Amano, Anna Ogiso, Tomohiro Akashi, Tohru Maeda, Norio Kaneda and 8 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Koya SuzukiDepartment of Pharmacology, Teikyo University School of Medicine, Itabashi-ku, Japan.ORCID http://orcid.org/0000-0001-5284-7957
Shinichi KiyonariDepartment of Biochemistry, Kitasato University School of Medicine, Sagamihara, Japan.ORCID http://orcid.org/0000-0002-4456-7186
Jo NishinoDivision of Bioinformatics, Research Institute, National Cancer Center Japan, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7057-3048
Miki TakahashiLaboratory of Cancer Molecular Genetics, Tokyo University of Technology Graduate School of Bionics, Computer and Media Sciences, Hachioji, Japan.ORCID http://orcid.org/0009-0006-2013-2408
Yuna KatoLaboratory of Cancer Molecular Genetics, Tokyo University of Technology Graduate School of Bionics, Computer and Media Sciences, Hachioji, Japan.ORCID http://orcid.org/0009-0000-8713-0163
Miki AmanoLaboratory of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.ORCID http://orcid.org/0009-0004-3266-6103
Anna OgisoLaboratory of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.ORCID http://orcid.org/0009-0009-0258-2212
Tomohiro AkashiDepartment of Integrative Cellular Informatics, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0003-3279-6149
Tohru MaedaCollege of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-9538-8559
Norio KanedaLaboratory of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Takashi MiidaDepartment of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University, Urayasu, Japan.ORCID http://orcid.org/0000-0002-4294-8030
Yutaka KondoDivision of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0003-3746-3191
Kenji KadomatsuInstitute for Glyco-core Research (iGCORE), Nagoya University, Nagoya, Japan.
Mamoru KatoDivision of Bioinformatics, Research Institute, National Cancer Center Japan, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8485-8316
Koji AoyamaDepartment of Pharmacology, Teikyo University School of Medicine, Itabashi-ku, Japan.ORCID http://orcid.org/0000-0003-4752-9262
Hiroshi MurakamiDepartment of Biological Science, Faculty of Science and Engineering, Chuo University, Bunkyo-ku, Japan.
Yoshitaka SekidoDivision of Cancer Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID http://orcid.org/0000-0002-2428-3848
Yuko Murakami-TonamiLaboratory of Cancer Molecular Genetics, Tokyo University of Technology Graduate School of Bionics, Computer and Media Sciences, Hachioji, Japan. murakamiyk@stf.teu.ac.jp.ORCID http://orcid.org/0000-0002-6347-1630

Funding

Japan Agency for Medical Research and Development (AMED) JP19ck0106368MEXT | Japan Society for the Promotion of Science (JSPS) JP18K06979MEXT | Japan Society for the Promotion of Science (JSPS) JP21K06863
6 · The paper itself

Abstract

BRCA1-associated protein 1 (BAP1) is frequently inactivated in pleural mesothelioma and functions as a tumor suppressor through its deubiquitinating activity. In this study, we investigated the context-dependent interplay between BAP1 and ubiquitin-specific protease 1 (USP1) in mesothelioma cells, focusing on their roles in regulating FANCD2, cell proliferation, and DNA damage responses. Genetic suppression of USP1 selectively inhibited cell proliferation in BAP1-deficient mesothelioma cells, whereas reintroduction of wild-type BAP1 rescued this growth defect; notably, a catalytically inactive BAP1 mutant failed to do so, indicating that BAP1 deubiquitinase activity is required for this compensation. In contrast, depletion of FANCD2 suppressed cell proliferation irrespective of BAP1 status, underscoring the essential role of FANCD2 in mesothelioma cell survival. Although both BAP1 and USP1 were capable of deubiquitinating FANCD2 in vitro, USP1 suppression in mesothelioma cells did not provide clear biochemical evidence of altered FANCD2 ubiquitination. Instead, USP1 knockdown was associated with reduced FANCD2 transcript and protein levels, without markedly affecting FANCD2 mRNA stability. At the cellular level, USP1 depletion impaired FANCD2 focus formation and reduced its colocalization with γ-H2AX in BAP1-deficient cells, consistent with defective DNA damage signaling. Despite these changes, homologous recombination (HR) efficiency was largely preserved, whereas non-homologous end joining activity was modestly increased upon USP1 suppression. Consistent with these in vitro findings, USP1 knockdown suppressed tumor growth in an intrathoracic xenograft model. Collectively, our results indicate that BAP1 and USP1 appear to regulate FANCD2 through distinct, context-dependent mechanisms, with USP1 primarily influencing FANCD2 expression and BAP1 modulating FANCD2 function at the post-translational level. Together, these findings identify USP1 as a context-dependent therapeutic vulnerability in BAP1-deficient mesothelioma and support a working model in which USP1-dependent maintenance of FANCD2 function becomes critical in the absence of functional BAP1.

Indexed as

Fanconi Anemia Complementation Group D2 ProteinMesotheliomaTumor Suppressor ProteinsUbiquitin-Specific ProteasesUbiquitin ThiolesteraseAnimalsCell Line, TumorCell ProliferationDNA DamageHumansMiceProtein StabilityUbiquitinationBAP1 protein, humanFANCD2 protein, humanFanconi Anemia Complementation Group D2 ProteinTumor Suppressor ProteinsUbiquitin-Specific ProteasesUbiquitin ThiolesteraseUSP1 protein, human

Identifiers

PMID42069682
PMCPMC13279938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.